Semaglutide in Canada: The Complete Research Guide to the GLP-1 Peptide
Semaglutide is the most widely studied GLP-1 receptor agonist in modern metabolic research, and one of the most searched research peptides in Canada. This guide breaks down the peptide's structure, the published STEP trial programme, dosages from clinical studies, sex-specific findings, reconstitution protocols, and what Canadian researchers should check before sourcing. For research context only.
What is semaglutide?
Semaglutide is a 31-amino-acid peptide analogue of human glucagon-like peptide-1 (GLP-1). Novo Nordisk developed it with a C-18 fatty diacid side chain linked to the peptide backbone. This modification lets the molecule bind to albumin (a protein in blood), which protects it from being broken down by enzymes. The result is a plasma half-life of roughly 7 days, making once-weekly dosing practical in research protocols.
The molecule shares 94% of its amino acid sequence with native human GLP-1(7-37). A key substitution at position 8 (Aib instead of the natural amino acid) makes it resistant to DPP-4, an enzyme that normally chews up GLP-1 within minutes. Semaglutide is an investigational research compound in Canada and is not sold for therapeutic use.
GLP-1 receptor agonism explained
GLP-1 is an incretin hormone. Your gut releases it after you eat. It works through the GLP-1 receptor, a type of G-protein-coupled receptor found in the pancreas, gut, brain, and cardiovascular system. Semaglutide is a single agonist. It activates the GLP-1 receptor exclusively, nothing else.
Pancreatic signalling
When the GLP-1 receptor is activated, it boosts glucose-dependent insulin secretion from beta cells and suppresses glucagon release from alpha cells. In plain terms, it helps regulate blood sugar from two directions at once. This dual action on the pancreatic islets is central to the compound's role in glycaemic research.
Central appetite pathways
GLP-1 receptors in the hypothalamus and brainstem play a role in satiety signalling and food-reward processing. Both preclinical and clinical data indicate that semaglutide acts on these central pathways. This helps explain the reductions in energy intake seen across trial populations.
Gastric motility
GLP-1 receptor activation slows gastric emptying, meaning food stays in the stomach longer after a meal. This mechanism is thought to contribute to both the appetite effects and the gastrointestinal side-effect profile reported in published studies.
Clinical trial data: the STEP programme
The STEP (Semaglutide Treatment Effect in People with Obesity) programme is the largest clinical trial series for any GLP-1 agonist. It spans multiple Phase 3 trials with thousands of participants.
Key published results
STEP 1 (2021): At the 2.4 mg dose over 68 weeks, participants showed mean body-weight reductions of 14.9% versus 2.4% with placebo. One-third of participants achieved weight reductions exceeding 20%.
STEP 5 (2022): Two-year data confirmed sustained effects. Participants maintained a mean weight reduction of 15.2% at 104 weeks, showing the compound's effects held up over extended research periods without significant drop-off.
SELECT (2024): This cardiovascular outcomes trial enrolled over 17,600 participants. It reported a 20% reduction in major adverse cardiovascular events (MACE), establishing a cardiovascular signal that went beyond metabolic endpoints alone.
STEP UP (2025): A higher 7.2 mg dose achieved mean weight reductions of approximately 20.7% at 72 weeks. That exceeded the 2.4 mg benchmark and expanded the dose-response curve for the compound.
Dosages used in published research
The following dose tiers reflect concentrations used across the STEP programme and related clinical studies. All published protocols used gradual escalation to the target maintenance dose.
STEP programme dose tiers (once-weekly, subcutaneous)
| Dose | Role in study design |
|---|---|
| 0.25 mg | Starting dose in escalation protocols. Used for initial tolerability assessment during weeks 1 to 4. |
| 0.5 mg | First escalation step. Some protocols kept participants here as a low-dose comparator. |
| 1.0 mg | Intermediate dose. This was the primary maintenance dose in the glycaemic-focused SUSTAIN programme. |
| 1.7 mg | Additional escalation step in the obesity programme. Acts as a bridge to the 2.4 mg target. |
| 2.4 mg | Standard maximum dose in the STEP programme. The most widely reported dose in obesity-related publications. |
| 7.2 mg | Higher dose evaluated in STEP UP (2025). Produced the largest weight reductions reported for this compound to date. |
Escalation protocol from published literature
The standard escalation started at 0.25 mg weekly for four weeks, then increased by one dose tier every four weeks: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg. The full ramp-up took 16 to 20 weeks. In the STEP UP trial, escalation continued beyond 2.4 mg through 3.6 mg and 5.4 mg tiers to reach 7.2 mg. The slow titration was designed to improve gastrointestinal tolerability.
Research findings: male vs female populations
Sex-stratified data from the STEP programme and related semaglutide trials have been published across multiple endpoints. The table below summarises observed patterns in male and female study populations. These are clinical and preclinical observations, not outcomes promised for anyone.
| Research area | Observations in male populations | Observations in female populations |
|---|---|---|
| Body composition | Greater absolute weight loss in kilograms observed in some cohorts. Higher proportion of visceral-fat reduction reported. | Greater percentage body-weight reduction observed in some cohorts. Subcutaneous-fat distribution patterns noted alongside baseline BMI differences. |
| Metabolic markers | Improvements in fasting glucose, HbA1c, and insulin sensitivity reported. LDL and triglyceride reductions also examined. | Comparable glycaemic improvements. HDL changes and lipid-panel responses studied alongside hormonal-cycle considerations. |
| Gastrointestinal tolerability | Nausea incidence generally lower than in female cohorts. Constipation reported as a common side effect. | Higher incidence of nausea reported across most STEP trial arms. Slower escalation schedules studied as a mitigation strategy. |
| Cardiovascular outcomes | SELECT trial showed significant MACE reduction. Blood-pressure and lipid improvements studied. | Consistent cardiovascular benefit observed. Sex-stratified STEP-HFpEF data showed similar improvements in heart-failure symptoms regardless of sex. |
| Appetite & satiety | Reductions in hunger and food cravings reported. Food-reward pathway modulation studied via neuroimaging. | Comparable appetite suppression observed. Potential interactions with menstrual-cycle-related appetite variation examined in some sub-studies. |
| Reproductive & hormonal | No significant effects on testosterone or gonadal-axis markers reported in published data. | Menstrual-cycle regularity changes noted. Fertility-related considerations flagged for researchers studying reproductive-age populations. |
Both sexes showed meaningful responses across the dose range. The STEP-HFpEF sex-stratified analysis specifically concluded that benefits were consistent between men and women. Researchers should consult the primary publications for full subgroup analyses.
Semaglutide vs tirzepatide vs retatrutide
| Feature | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Receptor targets | GLP-1 | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Agonist class | Single | Dual | Triple |
| Administration | Once weekly | Once weekly | Once weekly |
| Amino acids | 31 | 39 | 39 |
| Half-life | ~7 days | ~5 days | ~6 days |
| Max studied dose | 7.2 mg | 15 mg | 12 mg |
| Peak weight reduction | ~15–21% | ~22–25% | ~24–28%+ |
| Development stage | Approved (Ozempic/Wegovy) | Approved (Mounjaro/Zepbound) | Phase 3 (investigational) |
Semaglutide remains the reference compound in GLP-1 research. It is the single-agonist baseline against which dual and triple agonists are measured. Its extensive published dataset makes it the most well-characterised peptide in this class.
Reconstitution & storage
Reconstitution
Semaglutide is supplied as a lyophilized (freeze-dried) powder for research purposes. Reconstitute with bacteriostatic water (0.9% benzyl alcohol). A common laboratory preparation uses 1 mL of bacteriostatic water per 5 mg vial, yielding a concentration of 5 mg/mL (5000 mcg/mL). Add the water slowly down the inside wall of the vial. Do not shake. Swirl gently until the powder is fully dissolved. Use our reconstitution calculator for precise concentration math.
Storage
- Lyophilized (unreconstituted): −20 °C for long-term storage, or 2–8 °C for up to 24 months. Protect from light and moisture.
- Reconstituted: 2–8 °C. Use within 28 days. Do not freeze reconstituted peptide.
- General handling: Use sterile technique. Avoid repeated freeze-thaw cycles. Aliquot into single-use volumes where practical.
How to verify purity: COA & HPLC
Because semaglutide is the most studied GLP-1 agonist, its reference data is well established. That makes independent purity verification straightforward. A per-batch COA and HPLC purity figure are the standard quality checks.
Every 94 Supreme batch ships with its own COA
Third-party tested to HPLC ≥99%, per batch. See the certificates.
Frequently asked questions
Is semaglutide available in Canada for research?
Yes. Semaglutide is available as a research peptide in Canada from qualified suppliers such as 94 Supreme Peptides. It is sold strictly for laboratory and research purposes, not for therapeutic use or human consumption.
What purity should I expect?
Reputable Canadian suppliers provide semaglutide at 99%+ purity, verified by third-party HPLC analysis with per-batch COAs. Always request and review the COA before beginning any research protocol.
How is semaglutide different from tirzepatide?
Semaglutide is a single agonist that targets only the GLP-1 receptor. Tirzepatide is a dual agonist that targets both GLP-1 and GIP receptors. That additional GIP agonism introduces complementary metabolic signalling not present in semaglutide, which helps explain the higher weight-reduction figures reported in comparative literature.
What is the difference between the 2.4 mg and 7.2 mg dose?
The 2.4 mg dose was the standard maximum in the original STEP programme, producing mean weight reductions of approximately 15%. The 7.2 mg dose, evaluated in STEP UP (2025), produced mean reductions exceeding 20%. That significantly extended the dose-response curve. Both used the same gradual escalation approach.
How should I reconstitute semaglutide for research?
Add bacteriostatic water slowly down the inside wall of the vial. Do not shake. Swirl gently instead. A typical reconstitution uses 1 mL of bacteriostatic water per 5 mg vial (5 mg/mL). Use our reconstitution calculator for precise concentration math.
Research semaglutide, tested and shipped from Canada
HPLC ≥99%, a COA for every batch, and 1–3 day Xpress Post across Canada.
References
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. PubMed
- Garvey WT, Batterham RL, Bhatt DL, et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. Nature Medicine
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2024). Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). New England Journal of Medicine. PubMed
- Knop FK, Aroda VR, do Vale RD, et al. (2025). Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP). The Lancet Diabetes & Endocrinology. The Lancet
- Kosiborod MN, et al. (2024). Efficacy of semaglutide by sex in obesity-related HFpEF: STEP-HFpEF trials. JACC. JACC
Citations point to PubMed, Nature Medicine, The Lancet and JACC so you can read the primary sources directly.
For research use only. Not for human or veterinary consumption. This article is educational and summarises published clinical-trial and preclinical research; it is not medical advice. Products are sold strictly as research chemicals.